HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® ...

Johnson & Johnson secured fast-track status for its autoimmune drug Imaavy, accelerating the regulatory timeline for what could become the first approved treatment for warm autoimmune hemolytic anemia ...

Cold antibody hemolytic anemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells by autoantibodies at temperatures of approximately 0 to 10 degrees Celsius. Q ...

Autoimmune hemolytic anemia (AIHA) and paroxysmal nocturnal hemoglobinuria (PNH) are distinct blood disorders with different underlying causes and treatment approaches. Each is rare and potentially ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia ...

Investing.com -- The U.S. Food and Drug Administration granted Priority Review to Johnson & Johnson’s (NYSE:JNJ) supplemental biologics license application for IMAAVY (nipocalimab-aahu) as a treatment ...